New research examines the effects of newer drugs for Alzheimer’s disease.

HOBOKEN, N.J. – November 14, 2022 – Wiley, a global leader in research and education and publisher of the Cochrane Library, opened submissions today for Cochrane Evidence Synthesis and Methods, ...

A newly published Cochrane systematic review examining amyloid-beta-targeting monoclonal antibodies in Alzheimer's disease ...

In the fields of health and medicine, the Cochrane Database of Systematic Reviews may be the most trusted source of information. So when a massive Cochrane review finds that face-masking likely did ...

The logic of the Cochrane Collaboration remains unassailable. No one individual or group can keep abreast of the thousands of randomized trials that appear in the medical literature each year. The ...

The Cochrane Library is a collection of six databases that contain different types of high-quality, independent evidence to inform healthcare decision-making, and a seventh database that provides ...

The Cochrane Collaboration is an international, not–for–profit organisation that aims to help people make well–informed decisions about health care by preparing, maintaining and promoting the ...

This second article in a series on sources of evidence looks at the Cochrane Library. This library contains several electronic databases most notable of which is the Cochrane Database of Systematic ...

For adults with mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease, amyloid-beta-targeted monoclonal antibodies have negligible or little effect, according to a study published ...